Published Date: 26 Apr 2023
Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have developed a promising injectable cell therapy for osteoarthritis that not only lowers inflammation but also regenerates articular cartilage.
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC
2.
Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.
3.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
4.
Breast Cancer Incidence Increased Due to Particulate Air Pollution, According to NIH Study.
5.
How the skin cancer virus outperforms the replication of host cells.
1.
Everything You Need to Know About HTLV: A Comprehensive Guide
2.
Beyond the Cure: The Emerging Role of Tissue-Agnostic Therapies in Palliative Oncology
3.
Navigating the Complexities of Esophageal Cancer Staging
4.
Beyond the Biopsy: The Evolving Landscape of Prostate Cancer Management
5.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
2.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation